Faron Pharmaceuticals Ltd (LON:FARN) CEO Dr Markku Jalkanen caught up with Proactive to run through the company's 2016 results and outlook for the year ahead.
Traumakine, used to treat acute respiratory distress syndrome, is undergoing a phase III clinical trial with results expected in the second half.
Traumakine is now being developed for a second indication, a condition called rupture of abdominal aorta aneurysm.
Price: 405 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...
Prev article
